Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:PDLI

PDL BioPharma (PDLI) Stock Price, News & Analysis

PDL BioPharma logo

About PDL BioPharma Stock (NASDAQ:PDLI)

Key Stats

Today's Range
$2.47
$2.47
50-Day Range
$2.47
$2.47
52-Week Range
$2.09
$3.86
Volume
N/A
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive PDLI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PDL BioPharma and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

PDLI Stock News Headlines

GT Biopharma Inc GTBP
Health Winners & Losers: Maxygen
An $8 trillion-dollar discovery 17,000 ft underwater
A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materials critical for AI chips, EV batteries, smartphones, and advanced weapons systems. While few people know about these metals, global powers—including the U.S., China, and Russia—are racing to secure them. And one tiny public company, recently backed by the U.S. government, holds mining rights to over 340 million tons… and near-monopoly access to the richest zone.tc pixel
PDLI Historical Data
ABVC - ABVC BioPharma, Inc.
RDHL - RedHill Biopharma Ltd.
LABP
See More Headlines

PDLI Stock Analysis - Frequently Asked Questions

PDL BioPharma, Inc. (NASDAQ:PDLI) announced its earnings results on Thursday, August, 6th. The biotechnology company reported ($0.43) EPS for the quarter, missing the consensus estimate of $0.10 by $0.53. The biotechnology company had revenue of $5.21 million for the quarter.

Based on aggregate information from My MarketBeat watchlists, some other companies that PDL BioPharma investors own include AT&T (T), OPKO Health (OPK), Advanced Micro Devices (AMD), Canopy Growth (CGC), Novavax (NVAX), Pfizer (PFE) and Sorrento Therapeutics (SRNE).

Company Calendar

Last Earnings
8/06/2020
Today
10/17/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:PDLI
CIK
882104
Employees
109
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
13.00
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Optionable
Beta
N/A
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (NASDAQ:PDLI) was last updated on 10/17/2025 by MarketBeat.com Staff
From Our Partners